Daily Trades
- Dylan Jovine
- Friday, October 13, 2023
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
- Friday, August 18, 2023
Wanted to follow up on my controversial recommendation of Apellis (SYM: APLS) Wednesday.
- Dylan Jovine
- Wednesday, August 16, 2023
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
- Dylan Jovine
- Sunday, July 30, 2023
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42.
- Dylan Jovine
- Wednesday, June 14, 2023
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
- Wednesday, April 26, 2023
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
- Tuesday, February 28, 2023
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
- Dylan Jovine
- Friday, October 13, 2023
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
- Friday, August 18, 2023
Wanted to follow up on my controversial recommendation of Apellis (SYM: APLS) Wednesday.
- Dylan Jovine
- Wednesday, August 16, 2023
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
- Dylan Jovine
- Sunday, July 30, 2023
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42.
- Dylan Jovine
- Wednesday, June 14, 2023
Let's start by closing out one of our older positions for a small profit.
- Dylan Jovine
- Wednesday, April 26, 2023
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
- Dylan Jovine
- Tuesday, February 28, 2023
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
deal of the month
Categories
Dylan Jovine - "Uncovering the Game-Changing Drug of the Decade"
Protecting Your Financial Security from China's Attack on the US Dollar
Fed Rates Impacting Bonds: Explaining Maturity Length
Recent posts
Tags
Connect with Us
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
